Google Releases new State of the Art Model - Gemini 3

• Gemini 3 Deep Think scores 93.8% on the GPQA Diamond expert science benchmark and Gemini 3 Pro hits 81% on MMMU-Pro, demonstrating state-of-the-art multimodal reasoning and reliable tool-driven workflows.

• Pharmacy teams can treat Gemini 3 as an agentic coworker—able to automate multi-step digital tasks (chart review support, documentation drafts, inventory rebalancing, supply-chain alerts)—with pharmacists remaining responsible for clinical oversight and governance.

• Hospital pharmacy workflows are dense and digital—EHR review, inventory monitoring, order verification, and cross-team communication—but most existing tools are passive references that cannot reason across modalities or execute multi-step workflows.

• Gemini 3 is designed for complex, long-context synthesis and tool-driven actions and is being embedded into everyday Google products, aligning with how pharmacy teams already search, communicate, and document.

• As expectations rise for real-time stewardship, high-quality clinical decision support (CDS), and tighter operational control under fixed or shrinking FTEs, understanding Gemini 3’s agentic capabilities and safety guardrails is critical for planning sustainable automation.

• Built and released Gemini 3 (Gemini 3 Pro and Gemini 3 Deep Think): a native multimodal, agentic model with a 1-million-token context window, direct tool access via Google Antigravity (browser, terminal, code editor), and integrations into AI Mode in Search, the Gemini app, AI Studio, and Vertex AI.

• Validated performance across a broad benchmark suite (GPQA Diamond, Humanity's Last Exam, MMMU-Pro/Video-MMMU, Vending-Bench 2, ScreenSpot-Pro, Terminal-Bench, SWE-bench Verified, SimpleQA Verified) with side-by-side comparisons to prior Gemini versions and competing models.

• Performed layered safety and robustness testing: in-house Frontier Safety evaluations, independent red-team assessments, and staged safety tester access; Gemini 3 Deep Think received additional gating before wider rollout.

• Gemini 3 Deep Think reached 93.8% on GPQA Diamond (Gemini 3 Pro 91.9%) and 41.0% on Humanity’s Last Exam (Pro 37.5%), showing marked gains in expert-level, multi-step reasoning.

• Multimodal strengths — Video-MMMU 87.6% and ScreenSpot-Pro 72.7% — indicate reliable video and screen understanding, enabling visual sterile-compounding audits and automated interaction with legacy pharmacy user interfaces.

• Agentic/tool use: Terminal-Bench 54.2% and Vending-Bench 2 (Gemini 3 Pro ≈ $5,478 average returns) demonstrate consistent long-horizon planning and executable workflows suited to inventory rebalancing and shortage response.

• Engineering lift: SWE-bench Verified 76.2% and WebDev Arena 1487 Elo support rapid 'vibe coding' to build dashboards, stewardship apps, and automation without heavy IT involvement. The primary drivers were Gemini 3 Deep Think (System 2 reasoning), native multimodality, and integrated tool access via Antigravity.

• Expect a shift from static chatbots to agents that perform digital work—summarizing records, organizing information, running analyses—letting pharmacists spend more time on complex clinical tasks.

• Multimodal reasoning and a long context window enable single requests to synthesize notes, labs, guidelines, and images into coherent drafts or safety flags, supporting more consistent stewardship and discharge decisions.

• Operationally, treat Gemini 3 like a very strong resident or analyst: excellent for first-pass reviews, automation of routine tasks, and drafting, but still requiring pharmacist judgment on edge cases and high-stakes decisions.

Strengths:

• Broad, state-of-the-art benchmark suite spanning reasoning, multimodal understanding, coding, tool use, and long-horizon planning provides strong, multi-dimensional evidence of capability.

• Layered safety approach—Frontier Safety testing, external subject-matter experts, independent assessments, and a staged Deep Think rollout—supports responsible introduction into clinical environments.

Limitations:

• Evidence is primarily benchmark- and example-based; the article offers limited insight into real-world performance, operational failure modes, and longitudinal outcomes in live clinical settings.

• Technical specifics and governance controls are deferred to external documents (model card, evaluation methodology) and require further review before deployment in high-stakes clinical workflows.

Gemini 3 is appropriate for carefully governed pilots as an agentic pharmacy coworker and automation platform, but it is not yet a substitute for unsupervised high-stakes clinical decision-making.